Cure Ventures

Great to see Tasca's Series A news light up Times Square! This is a big first step but many more to go. Cure Ventures is building companies for the long haul and Tasca perfectly illustrates that. More to come from us, all!

We formed Cure Ventures to not just be another venture fund - we wanted to focus on company formation around ground-breaking curative technologies.    Tasca Therapeutics is Cure Ventures' first portfolio company grown in-house and today announced a $52 Million Series A financing to progress their lead program, CP-383, into Phase 1/2 clinical proof-of-concept studies.    With its exceptional science and strong leadership, Tasca exactly illustrates the type of transformative company that Cure is looking to build. We are thrilled to have milenko cicmil as chief executive officer and Praveen Tipirneni, M.D., and chairman of the board.    The prospect of being able to drug previously undruggable targets in oncology and potentially other indications differentiates Tasca from the competition. We’re confident in Tasca’s programs and look forward to supporting them as they advance their platform and pipeline. We'll be sharing more portfolio company updates in 2025.    For more information about Tasca Therapeutics, please visit https://www.tascatx.com/ Photo of Tasca leadership, left to right: David E. Fisher, M.D.,Ph.D; Scientific Co-founder, Milenko Cicmil, Ph.D., Co-founder and CEO, Xu Wu, Ph.D., Co-founder and Director.

We're #hiring a new Venture Associate in Boston, Massachusetts. Apply today or share this post with your network.

Cure partner Jeffrey Jonas talked with CNN today to provide his opinion on the upcoming potential insulin shortage. He offers both an expert industry perspective and that of a concerned father whose son relies on insulin for type 1 diabetes. Read the full article here: https://lnkd.in/gsmbhUjU

We’re excited to share that our portfolio company, Kenai Therapeutics, recently closed an $82M Series A financing. Kenai is a biotechnology company pioneering next generation approaches to cure neurological disorders. The Company’s platform replaces neurons lost due to neurodegeneration in the brain in order to dramatically alter outcomes for patients. RNDP-001, the Company’s lead candidate, is being developed for the treatment of Parkinson’s disease and is currently in IND-enabling studies. Proceeds from the financing will enable the Company to submit an IND and initiate Phase 1 clinical trials within the next year. Parkinson’s disease affects millions of people worldwide, and the potentially curative nature of RNDP-001 can dramatically alter outcomes for patients with very few treatment options. Congratulations to the Kenai team on this significant milestone! We’re looking forward to what’s to come. Read the press release below:    #venturecapital #lifescience #biotech

Exclusive: The dream of being able to pluck a cell therapy off of a freezer shelf and speedily give it to patients is materializing in the cancer world. Now, a new biotech hopes to do the same for patients with neurological conditions. The company, Kenai Therapeutics, just closed a $82 million Series A round co-led by Cure Ventures, The Column Group, and sovereign wealth fund Alaska Permanent Fund Corporation. The San Diego-based biotech has big plans for that money — it’s already identified its lead drug candidate for people with Parkinson’s disease, and plans to move into a clinical trial. #biotech #biopharma #lifesciences #celltherapy #startups #clinicaltrials #neuroscience #parkinsonsdisease #neurodegenerative #seriesA #fundraising #venturecapital #vc

Our latest stealth company is #hiring a Platform Director. Check out our job posting for more details.